Page last updated: 2024-08-21

fluorobenzenes and Stroke

fluorobenzenes has been researched along with Stroke in 46 studies

Research

Studies (46)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (2.17)	18.2507
2000's	14 (30.43)	29.6817
2010's	31 (67.39)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ahn, SH; Chamorro, Á; Choi, DW; Choi, MH; Hong, JM; Hwang, YH; Lee, YB; Shin, DI; Sohn, SI	1
Balu, S; Montouchet, C; Ruff, L	1
Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K	1
Glynn, RJ; Mora, S; Ridker, PM	1
Daida, H; Daimon, M; Hattori, N; Kuroki, T; Miyamoto, N; Miyauchi, K; Shimada, Y; Tanaka, R; Tanaka, Y; Ueno, Y; Urabe, T; Watanabe, M; Yamashiro, K	1
Askevold, ET; Aukrust, P; Gravning, J; Gullestad, L; Kjekshus, J; McMurray, JJ; Nymo, SH; Ueland, T; Wikstrand, J	1
Borg, JY; Guegan-Massardier, E; Joly, B; Le Cam-Duchez, V; Menard, AL; Ozkul-Wermester, O; Triquenot-Bagan, A	1
Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A	1
Li, L; Tian, JH; Yang, K; Zhang, P	1
Homma, S; Ye, S	1
Abdul-Rahim, AH; Fulton, RL; Jhund, PS; Kjekshus, J; Latini, R; Lees, KR; Lip, GY; Maggioni, AP; McMurray, JJ; Perez, AC; Tavazzi, L; Tognoni, G; Wikstrand, J	2
Blankenberg, S; Everett, BM; Glynn, RJ; Ridker, PM; Zeller, T	1
Hung, Y; Li, YH; Lin, GM	1
Danielson, E; Fonseca, FA; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Ridker, PM; Shepherd, J; Willerson, JT	1
Dobson, R	1
Chalita-Williams, C; Gonzalez-Aguirre, D; Gordillo-Moscoso, A; Rodriguez-Leyva, I; Sanchez-Aguilar, M; Tapia-Perez, H; Torres-Corzo, JG	1
Kones, R	1
Fonseca, FA; Izar, MC	1
Everett, BM; Glynn, RJ; MacFadyen, JG; Ridker, PM	1
Fonseca, FA; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Ridker, PM; Shepherd, J; Willerson, JT	1
Genest, J; Glynn, RJ; Hsia, J; MacFadyen, JG; Mora, S; Ridker, PM	1
Ballerio, R; Banfi, C; Blanc-Guillemaud, V; Brioschi, M; Castiglioni, L; Gelosa, P; Gianella, A; Guerrini, U; Lerond, L; Nobili, E; Pignieri, A; Sironi, L; Tremoli, E	1
Grammer, TB; März, W	1
Boekholdt, SM; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Libby, P; MacFadyen, JG; Mora, S; Nordestgaard, BG; Ridker, PM	1
Neft, M	1
Crisby, M; Famer, D; Wahlund, LO	1
Koenig, W; Ridker, PM	1
Drexel, H; Saely, CH; Vonbank, A	1
Cho, SI; Chung, JM; Gwag, BJ; Park, UJ	1
Algra, A; de Wit, GA; Greving, JP; Visseren, FL	1
Serebruany, VL	1
Adourian, A; Aukrust, P; Böhm, M; Cleland, JG; Gullestad, L; Hulthe, J; Kjekshus, J; Komajda, M; McMurray, JJ; Muntendam, P; Nymo, SH; Ueland, T; van Veldhuisen, DJ; Wikstrand, J	1
Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A	1
Fujisawa, M; Igase, M; Katagi, R; Kohara, K; Miki, T; Yamashita, S	1
Kamal, AK; Khan, M; Raza, E	1
Aukrust, P; Gullestad, L; Hulthe, J; Kjekshus, J; McMurray, JJ; Muntendam, P; Nymo, SH; Ueland, T; Wikstrand, J	1
Kanorskiĭ, SG; Shevelev, VI	1
Bassetti, CL; Hermann, DM; Kilic, E; Kilic, U; Lüscher, TF; Matter, CM	1
Cremonesi, B; Gelosa, P; Gianazza, E; Gianella, A; Guerrini, U; Nobili, E; Paoletti, R; Sironi, L; Tremoli, E	1
Abbate, M; Banfi, C; Bellosta, S; Brioschi, M; Canavesi, M; Gelosa, P; Gianella, A; Guerrini, U; Mussoni, L; Nobili, E; Remuzzi, G; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C	1
Orr, JD	1
Artman, LD; Balandrin, MF; Brady, E; Chien, Y; Delmar, EG; George, K; Kierstead, A; Marriott, TB; Moe, ST; Mueller, AL; Newman, MK; Raszkiewicz, JL; Sanguinetti, EL; van Wagenen, BC; Wells, D	1
Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Nickenig, G	1

Reviews

8 review(s) available for fluorobenzenes and Stroke

Article	Year
Statins for primary prevention of venous thromboembolism. The Cochrane database of systematic reviews, 2014, Dec-18, Issue:12 Topics: Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke; Sulfonamides; Venous Thromboembolism; Venous Thrombosis	2014
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Circulation, 2015, Apr-28, Volume: 131, Issue:17 Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Benzimidazoles; Biomarkers; Biphenyl Compounds; Cardiovascular Agents; Diabetes Mellitus, Type 1; Fatty Acids, Omega-3; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Proportional Hazards Models; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Stroke; Stroke Volume; Sulfonamides; Tetrazoles	2015
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease. Therapeutic advances in cardiovascular disease, 2009, Volume: 3, Issue:4 Topics: Angina, Unstable; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome	2009
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUP Circulation, 2010, Mar-09, Volume: 121, Issue:9 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Comorbidity; Double-Blind Method; Dyslipidemias; Early Termination of Clinical Trials; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Risk; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides; Treatment Outcome	2010
[C-reactive protein and coronary heart disease: quo vadis?]. MMW Fortschritte der Medizin, 2009, Volume: 151 Suppl 3 Topics: Alleles; Apolipoproteins E; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Haplotypes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Genetic; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides	2009
Neu2000, an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke. Drug news & perspectives, 2010, Volume: 23, Issue:9 Topics: Animals; Antioxidants; Benzoates; Brain Ischemia; Drug Delivery Systems; Fluorobenzenes; Humans; meta-Aminobenzoates; Neuroprotective Agents; Receptors, N-Methyl-D-Aspartate; Salicylates; Spin Trapping; Stroke; Time Factors	2010
Statins in the spectrum of neurologic disease. Current atherosclerosis reports, 2008, Volume: 10, Issue:1 Topics: Alzheimer Disease; Animals; Atherosclerosis; Cardiovascular Diseases; Diabetic Neuropathies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Multiple Sclerosis; Nervous System Diseases; Neurodegenerative Diseases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pyrimidines; Reactive Oxygen Species; Rosuvastatin Calcium; Stroke; Sulfonamides	2008
NPS 1506, a novel NMDA receptor antagonist and neuroprotectant. Review of preclinical and clinical studies. Annals of the New York Academy of Sciences, 1999, Volume: 890 Topics: Adolescent; Adult; Animals; Brain Ischemia; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Learning; Male; Neuroprotective Agents; Propylamines; Receptors, N-Methyl-D-Aspartate; Stroke	1999

Trials

15 trial(s) available for fluorobenzenes and Stroke

Article	Year
Safety and Optimal Neuroprotection of neu2000 in acute Ischemic stroke with reCanalization: study protocol for a randomized, double-blinded, placebo-controlled, phase-II trial. Trials, 2018, Jul-13, Volume: 19, Issue:1 Topics: Brain Ischemia; Clinical Trials, Phase II as Topic; Disability Evaluation; Double-Blind Method; Endovascular Procedures; Fluorobenzenes; Humans; meta-Aminobenzoates; Multicenter Studies as Topic; Neuroprotective Agents; Prospective Studies; Randomized Controlled Trials as Topic; Recovery of Function; Republic of Korea; Salicylates; Stroke; Thrombectomy; Time Factors; Treatment Outcome	2018
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. European heart journal, 2013, Volume: 34, Issue:41 Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional	2013
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation, 2013, Sep-10, Volume: 128, Issue:11 Topics: Aged; Angina, Unstable; Apolipoprotein A-I; Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Endpoint Determination; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Nuclear Magnetic Resonance, Biomolecular; Particle Size; Proportional Hazards Models; Pyrimidines; Risk; Rosuvastatin Calcium; Single-Blind Method; Stroke; Sulfonamides; Triglycerides	2013
Rationale and design of the EPISTEME trial: efficacy of post-stroke intensive rosuvastatin treatment for aortogenic embolic stroke. Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:1 Topics: Aorta; Brain Ischemia; Echocardiography, Transesophageal; Embolism; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Research Design; Rosuvastatin Calcium; Stroke; Sulfonamides	2014
Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial. Circulation. Heart failure, 2014, Volume: 7, Issue:1 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Chronic Disease; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Prognosis; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sensitivity and Specificity; Stroke; Sulfonamides; Survival Rate; Troponin T	2014
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. American heart journal, 2014, Volume: 168, Issue:5 Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome	2014
High-sensitivity cardiac troponin I and B-type natriuretic Peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation, 2015, May-26, Volume: 131, Issue:21 Topics: Aged; Angina, Unstable; Biomarkers; Cholesterol, HDL; Comorbidity; Coronary Disease; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Primary Prevention; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Troponin T	2015
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England journal of medicine, 2008, Nov-20, Volume: 359, Issue:21 Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides	2008
Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation, 2010, Jan-05, Volume: 121, Issue:1 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Placebos; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides	2010
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention Circulation. Cardiovascular quality and outcomes, 2009, Volume: 2, Issue:6 Topics: Age Factors; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Endpoint Determination; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Myocardial Infarction; Myocardial Revascularization; Primary Prevention; Pyrimidines; Racial Groups; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides	2009
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUP Circulation, 2010, Mar-09, Volume: 121, Issue:9 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Comorbidity; Double-Blind Method; Dyslipidemias; Early Termination of Clinical Trials; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Myocardial Ischemia; Proportional Hazards Models; Pyrimidines; Risk; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides; Treatment Outcome	2010
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (London, England), 2010, Jul-31, Volume: 376, Issue:9738 Topics: Adult; Aged; Angina, Unstable; Angioplasty; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome	2010
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities. European heart journal, 2011, Volume: 32, Issue:1 Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides	2011
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European heart journal, 2012, Volume: 33, Issue:18 Topics: Aged; Biomarkers; C-Reactive Protein; Female; Fluorobenzenes; Galectin 3; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipid Metabolism; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome	2012
The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American heart journal, 2012, Volume: 164, Issue:6 Topics: Aged; Aged, 80 and over; Biomarkers; Female; Fluorobenzenes; Galectin 3; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides	2012

Other Studies

24 other study(ies) available for fluorobenzenes and Stroke

Article	Year
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective. Journal of medical economics, 2013, Volume: 16, Issue:7 Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States	2013
Involvement of Arg306 mutation in factor V gene in two young men with ischemic stroke. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2014, Volume: 25, Issue:8 Topics: Anticholesteremic Agents; Arginine; Aspirin; Brain Ischemia; DNA Mutational Analysis; Factor V; Fibrinolytic Agents; Fluorobenzenes; Humans; Intracranial Thrombosis; Male; Middle Aged; Mutation; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Young Adult	2014
Stroke and anticoagulation in heart failure without atrial fibrillation: from risk to opportunity. Circulation, 2015, Apr-28, Volume: 131, Issue:17 Topics: Fatty Acids, Omega-3; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyrimidines; Stroke; Sulfonamides	2015
Letter by Lin et al Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravv Circulation, 2015, Dec-01, Volume: 132, Issue:22 Topics: Fatty Acids, Omega-3; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyrimidines; Stroke; Sulfonamides	2015
Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvi Circulation, 2015, Dec-01, Volume: 132, Issue:22 Topics: Fatty Acids, Omega-3; Female; Fluorobenzenes; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyrimidines; Stroke; Sulfonamides	2015
Trial stopped early after rosuvastatin found to cut the risk of heart attack and stroke by 44% in healthy people. BMJ (Clinical research ed.), 2008, Nov-12, Volume: 337 Topics: Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides	2008
Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. Central European neurosurgery, 2009, Volume: 70, Issue:1 Topics: Adult; Aged; Antihypertensive Agents; Cerebral Hemorrhage; Female; Fluorobenzenes; Glasgow Coma Scale; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Odds Ratio; Pilot Projects; Proportional Hazards Models; Prospective Studies; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sample Size; Stroke; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome	2009
Rosuvastatin for cardiovascular prevention: too many uncertainties. Prescrire international, 2009, Volume: 18, Issue:102 Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty	2009
Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study. Expert review of cardiovascular therapy, 2009, Volume: 7, Issue:9 Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke; Sulfonamides	2009
Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. The Journal of pharmacology and experimental therapeutics, 2010, Volume: 334, Issue:1 Topics: Animals; Aspirin; Biomarkers; Blood Pressure; Brain; Endothelium, Vascular; Fluorobenzenes; Hypertension; Magnetic Resonance Imaging; Male; Naphthalenes; Propionates; Protective Agents; Pyrimidines; Rats; Rats, Inbred SHR; Receptors, Prostaglandin; Receptors, Thromboxane; Rosuvastatin Calcium; Stroke; Sulfonamides; Survival Analysis; Systemic Inflammatory Response Syndrome	2010
Interpreting and evaluating the details of the JUPITER study. American family physician, 2010, Sep-15, Volume: 82, Issue:6 Topics: Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides	2010
Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD. Biochemical and biophysical research communications, 2010, Nov-12, Volume: 402, Issue:2 Topics: Alzheimer Disease; Animals; Apolipoproteins E; Brain; Cholesterol; Diet; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Mice; Mice, Knockout; Microglia; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides	2010
HDL cholesterol and residual risk of first cardiovascular events. Lancet (London, England), 2010, Nov-20, Volume: 376, Issue:9754 Topics: Cholesterol, HDL; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides	2010
Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ (Clinical research ed.), 2011, Mar-30, Volume: 342 Topics: Aged; Cost-Benefit Analysis; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Myocardial Infarction; Pyrimidines; Quality-Adjusted Life Years; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome	2011
Extreme all-cause mortality in JUPITER requires reexamination of vital records. Cardiology, 2011, Volume: 120, Issue:2 Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Diabetic Angiopathies; Early Termination of Clinical Trials; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides	2011
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model. Journal of medical economics, 2012, Volume: 15, Issue:6 Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides	2012
Predictive value of the low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio for the prevention of stroke recurrence in Japanese patients treated with rosuvastatin. Clinical drug investigation, 2012, Aug-01, Volume: 32, Issue:8 Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Japan; Male; Multivariate Analysis; Predictive Value of Tests; Pyrimidines; Recurrence; Rosuvastatin Calcium; Stroke; Sulfonamides; Young Adult	2012
My patient has an elevated hs-CRP. What does this mean? What should I do now? JPMA. The Journal of the Pakistan Medical Association, 2012, Volume: 62, Issue:2 Topics: C-Reactive Protein; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides	2012
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation]. Klinicheskaia meditsina, 2012, Volume: 90, Issue:9 Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance	2012
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke, 2005, Volume: 36, Issue:2 Topics: Animals; Blotting, Western; Brain; Brain Ischemia; Enzyme Inhibitors; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ischemia; Laser-Doppler Flowmetry; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Pyrimidines; Rosuvastatin Calcium; Signal Transduction; Stroke; Sulfonamides; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator	2005
Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:3 Topics: Acute-Phase Proteins; Animals; Cerebral Arteries; Chemokine CCL2; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; P-Selectin; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sodium Chloride, Dietary; Stroke; Sulfonamides; Transcription, Genetic; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vasculitis	2005
Atorvastatin for stroke prevention. The Medical letter on drugs and therapeutics, 2006, Sep-11, Volume: 48, Issue:1243 Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors	2006
Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. The American journal of pathology, 2007, Volume: 170, Issue:4 Topics: Actins; Animals; Blood Pressure; Blotting, Western; Collagen; Disease Progression; Fibrinogen; Fibrinolysin; Fibrosis; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microscopy, Electron; Plasminogen Activator Inhibitor 1; Plasminogen Activators; Podocytes; Proteinuria; Pyrimidines; Rats; Rats, Inbred SHR; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides	2007
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain research, 2002, Jun-28, Volume: 942, Issue:1-2 Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Endothelium, Vascular; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Mice; Mice, Inbred Strains; Neuroprotective Agents; Nitric Oxide Synthase; Pyrimidines; Reperfusion Injury; RNA, Messenger; Rosuvastatin Calcium; Stroke; Sulfonamides; Up-Regulation	2002